Discover how AI healthcare technology and machine learning diagnosis are transforming disease detection, improving accuracy, and reshaping patient care in today's evolving medical landscape.

Funding will expand the range of Dualase(R) genome editors for new high morbidity and mortality genetic disease targets. TORONTO, March 18, 2026 /PRNewswire/ - Specific Biologics Inc. ("Specific"), a ...

Funding will expand the range of Dualase(R) genome editors for new high morbidity and mortality genetic disease targets. TORONTO, March 18, 2026 /CNW/ - Specific Biologics Inc. ("Specific"), a ...

Specific Biologics Inc. ("Specific"), a biotechnology company developing industry-leading in vivo genome editing medicines to treat the untreatable, today announced that together with Western ...

To use this evidence, investigators typically must grow the larvae until adulthood in a laboratory setting and then identify ...

The global preimplantation genetic testing market is growing steadily, valued at around US$ 598.4 million in 2026 and ...

The simulator takes into account forecasted demand in each region, transportation costs, and the operational capacity of each warehouse.

Romano-Ward syndrome, the most common congenital long QT disorder, often causes exertion- or stimulus-triggered syncope and ...

The global preimplantation genetic testing market is growing steadily, valued at around US$ 598.4 million in 2026 and projected to reach US$ 1,081.9 million ...

An interdisciplinary research team from two working groups at the Center for Synthetic Biology at TU Darmstadt has developed ...

Artificial intelligence (AI)-driven investment strategies could help pension schemes improve risk-adjusted returns without ...

Agreement Combines Tenaya’s Expertise in Identification and Validation ofGenetic Heart Disease Targets with Alnylam’s Ability ...